These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 9042848)

  • 1. Osteogenesis imperfecta. Rehabilitation and prospects for gene therapy.
    Marini JC; Gerber NL
    JAMA; 1997 Mar; 277(9):746-50. PubMed ID: 9042848
    [No Abstract]   [Full Text] [Related]  

  • 2. Validation in mesenchymal progenitor cells of a mutation-independent ex vivo approach to gene therapy for osteogenesis imperfecta.
    Millington-Ward S; Allers C; Tuohy G; Conget P; Allen D; McMahon HP; Kenna PF; Humphries P; Farrar GJ
    Hum Mol Genet; 2002 Sep; 11(19):2201-6. PubMed ID: 12217948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential of gene therapy for treating osteogenesis imperfecta.
    Niyibizi C; Smith P; Mi Z; Robbins P; Evans C
    Clin Orthop Relat Res; 2000 Oct; (379 Suppl):S126-33. PubMed ID: 11039761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Attempts to use gene therapy for reducing connective tissue disorders--osteogenesis imperfecta].
    Gajko-Galicka A
    Postepy Biochem; 2003; 49(1):18-25. PubMed ID: 14518394
    [No Abstract]   [Full Text] [Related]  

  • 5. Etiology of osteogenesis imperfecta: an overview of biochemical and molecular genetic analyses.
    Byers PH
    Connect Tissue Res; 1995; 31(4):257-9. PubMed ID: 15612363
    [No Abstract]   [Full Text] [Related]  

  • 6. A mutation-independent therapeutic strategem for osteogenesis imperfecta.
    Millington-Ward S; O'Neill B; Kiang AS; Humphries P; Kenna PF; Farrar GJ
    Antisense Nucleic Acid Drug Dev; 1999 Dec; 9(6):537-42. PubMed ID: 10645780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Approaches for skeletal gene therapy.
    Niyibizi C; Wallach CJ; Mi Z; Robbins PD
    Crit Rev Eukaryot Gene Expr; 2002; 12(3):163-73. PubMed ID: 12449341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of type I collagen gene (COL1A2) mutations in nonlethal osteogenesis imperfecta.
    Sztrolovics R; Glorieux FH; van der Rest M; Roughley PJ
    Hum Mol Genet; 1993 Aug; 2(8):1319-21. PubMed ID: 8401517
    [No Abstract]   [Full Text] [Related]  

  • 9. Cleavage of collagen RNA transcripts by hammerhead ribozymes in vitro is mutation-specific and shows competitive binding effects.
    Grassi G; Forlino A; Marini JC
    Nucleic Acids Res; 1997 Sep; 25(17):3451-8. PubMed ID: 9254703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in osteogenesis imperfecta.
    Cole WG
    Clin Orthop Relat Res; 2002 Aug; (401):6-16. PubMed ID: 12151877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hopkins Memorial Medal lecture. Pleasant surprises en route from the biochemistry of collagen to attempts at gene therapy.
    Prockop DJ
    Biochem Soc Trans; 1999 Feb; 27(2):15-31. PubMed ID: 10093701
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of growth hormone transgene expression on vertebrae in a mouse model of osteogenesis imperfecta.
    King D; Chase J; Havey RM; Voronov L; Sartori M; McEwen HA; Beamer WG; Patwardhan AG
    Spine (Phila Pa 1976); 2005 Jul; 30(13):1491-5. PubMed ID: 15990661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Substitution of glycine-172 by arginine in the alpha 1 chain of type I collagen in a patient with osteogenesis imperfecta, type III.
    Mackay K; De Paepe A; Nuytinck L; Dalgleish R
    Hum Mutat; 1994; 3(3):324-6. PubMed ID: 8019571
    [No Abstract]   [Full Text] [Related]  

  • 14. Recurrence of lethal osteogenesis imperfecta due to parental mosaicism for a mutation in the COL1A2 gene of type I collagen. The mosaic parent exhibits phenotypic features of a mild form of the disease.
    Edwards MJ; Wenstrup RJ; Byers PH; Cohn DH
    Hum Mutat; 1992; 1(1):47-54. PubMed ID: 1301191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Normal collagen and bone production by gene-targeted human osteogenesis imperfecta iPSCs.
    Deyle DR; Khan IF; Ren G; Wang PR; Kho J; Schwarze U; Russell DW
    Mol Ther; 2012 Jan; 20(1):204-13. PubMed ID: 22031238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Substitution of arginine for glycine at position 154 of the alpha 1 chain of type I collagen in a variant of osteogenesis imperfecta: comparison to previous cases with the same mutation.
    Zhuang J; Tromp G; Kuivaniemi H; Castells S; Prockop DJ
    Am J Med Genet; 1996 Jan; 61(2):111-16. PubMed ID: 8669434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteogenesis imperfecta.
    Byers PH; Steiner RD
    Annu Rev Med; 1992; 43():269-82. PubMed ID: 1580589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel G1006A substitution in the alpha 2(I) chain of type I collagen produces osteogenesis imperfecta type III.
    Lu J; Costa T; Cole WG
    Hum Mutat; 1995; 5(2):175-8. PubMed ID: 7749416
    [No Abstract]   [Full Text] [Related]  

  • 19. Sequence of normal canine COL1A1 cDNA and identification of a heterozygous alpha1(I) collagen Gly208Ala mutation in a severe case of canine osteogenesis imperfecta.
    Campbell BG; Wootton JA; MacLeod JN; Minor RR
    Arch Biochem Biophys; 2000 Dec; 384(1):37-46. PubMed ID: 11147834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Gly859Ser substitution in the triple helical domain of the alpha 2 chain of type I collagen resulting in osteogenesis imperfecta type III in two unrelated individuals.
    Rose NJ; Mackay K; Byers PH; Dalgleish R
    Hum Mutat; 1994; 3(4):391-4. PubMed ID: 8081394
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.